Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Bemcentinib |
Synonyms | |
Therapy Description |
Bemcentinib (BGB-324) is a small molecule inhibitor of Axl, which inhibits tumor growth and may overcome EMT-mediated acquired drug resistance (PMID: 20145120, PMID: 31134766). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Bemcentinib | BGB 324|BGB-324|BGB324|R428|R-428 | AXL Inhibitor 30 | Bemcentinib (BGB-324) is a small molecule inhibitor of Axl, which inhibits tumor growth and may overcome EMT-mediated acquired drug resistance (PMID: 20145120, PMID: 31134766). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03965494 | Phase I | Bemcentinib | AXL Inhibitor BGB324 in Treating Participants With Recurrent Glioblastoma Undergoing Surgery | Terminated | USA | 0 |
NCT02488408 | Phase I | Cytarabine Bemcentinib | Multicenter Open-label Study of BGB324 as a Single Agent and in Combination With Cytarabine in Patients With AML | Unknown status | USA | NOR | ITA | DEU | 0 |